These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30945932)

  • 1. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 2. A new method for identification of outliers in immunogenicity assay cut point data.
    Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
    J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size consideration for immunoassay screening cut-point determination.
    Zhang J; Zhang L; Yang H
    J Biopharm Stat; 2014; 24(3):535-45. PubMed ID: 24697778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing efficiency and quality of statistical estimation of immunogenicity assay cut points through standardization and automation.
    Su C; Zhou L; Hu Z; Weng W; Subramani J; Tadkod V; Hamilton K; Bautista A; Wu Y; Chirmule N; Zhong ZD
    J Immunol Methods; 2015 Oct; 425():88-96. PubMed ID: 26130368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Alternative Data Transformation Approach for ADA Cut Point Determination: Why Not Use a Weibull Transformation?
    Jordan G; Staack RF
    AAPS J; 2021 Aug; 23(5):97. PubMed ID: 34389881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan.
    Ishii-Watabe A; Shibata H; Nishimura K; Hosogi J; Aoyama M; Nishimiya K; Saito Y
    Bioanalysis; 2018 Jan; 10(2):95-105. PubMed ID: 29243491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report on the AAPS Immunogenicity Guidance Forum.
    Myler H; Gorovits B; Phillips K; Devanarayan V; Clements-Egan A; Gunn GR; Kirshner S; DeSilva B; Shah VP
    AAPS J; 2019 Apr; 21(4):55. PubMed ID: 30993501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical approaches for the determination of cut points in anti-drug antibody bioassays.
    Schaarschmidt F; Hofmann M; Jaki T; Grün B; Hothorn LA
    J Immunol Methods; 2015 Mar; 418():84-100. PubMed ID: 25733352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summary of confirmation cut point discussions.
    Smith HW; Moxness M; Marsden R
    AAPS J; 2011 Jun; 13(2):227-9. PubMed ID: 21380610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity assay cut point determination using nonparametric tolerance limit.
    Zhang J; Li W; Roskos LK; Yang H
    J Immunol Methods; 2017 Mar; 442():29-34. PubMed ID: 28063769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?
    Jaki T; Allacher P; Horling F
    J Pharm Biomed Anal; 2016 Sep; 128():166-173. PubMed ID: 27262992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population.
    Tan CY; Steeno GS; You Z; Gaitonde P; Cai CH; Kamerud J; Gorovits B; Baltrukonis DJ
    AAPS J; 2020 Jan; 22(2):19. PubMed ID: 31900604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.
    Gunn GR; Sealey DC; Jamali F; Meibohm B; Ghosh S; Shankar G
    Clin Exp Immunol; 2016 May; 184(2):137-46. PubMed ID: 26597698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
    J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
    Song S; Yang L; Trepicchio WL; Wyant T
    J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical Approaches for Establishing Appropriate Immunogenicity Assay Cut Points: Impact of Sample Distribution, Sample Size, and Outlier Removal.
    Garlits J; McAfee S; Taylor JA; Shum E; Yang Q; Nunez E; Kameron K; Fenech K; Rodriguez J; Torri A; Chen J; Sumner G; Partridge MA
    AAPS J; 2023 Apr; 25(3):37. PubMed ID: 37016171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.